Orexo AB (FRA:C5G) FFO


FRA:C5G Orexo AB FRA:C5G
43 GF Score
Price €2.10
GF Value €0.55
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Orexo AB FFO?

FFO (Funds from operations) only applies to REITs.

FRA:C5G
43GF Score
Orexo AB FRA:C5G
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Orexo AB (FRA:C5G) Overvalued in 2026?

Based on GuruFocus' analysis, Orexo AB stock appears to be overvalued. The current stock price of €2.10 is trading 280.9% above its estimated GF Value™ of €0.55. GuruFocus considers Orexo AB to be Significantly Overvalued.

Key valuation signals for FRA:C5G:

  • FFO:
  • GF Value™: €0.55 vs. price of €2.10 (280.9% above fair value)
  • GF Score™: 43/100 with 8 warning signs

No single metric tells the full story. See the FRA:C5G stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Orexo AB Business Description

Address Virdings alle 22, Uppsala, SWE, 75105
Orexo AB is a Swedish pharmaceutical company dedicated to advancing treatments for severe diseases and life-saving rescue medications to meet future healthcare needs, developing improved medications based on proprietary drug delivery technologies. At the core of its innovation is AmorphOX, which improves bioavailability and stability for both large and small molecules. It has developed four drugs from concept to approval, including Zubsolv, Abstral, Edluar, and Diabact UBT. The company's current development efforts focus on AmorphOX, with projects in preclinical and clinical phases across multiple therapeutic areas. It operates through US Commercial and HQ & Pipeline, which generate maximum revenue, and operates in the US, EU, and UK generating maximum revenue, and the Rest of the World.
43GF Score

Get the complete analysis for FRA:C5G

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.10
Price
€0.55
GF Value